Key regions: France, Brazil, South Korea, India, China
The demand for Antiviral Drugs in Iran has been increasing steadily in recent years due to various factors.
Customer preferences: The Iranian population has a high prevalence of viral diseases, including hepatitis B and C, HIV, and influenza. As a result, there is a high demand for antiviral drugs in the country. The majority of customers in Iran prefer generic antiviral drugs due to their lower cost compared to branded drugs.
Trends in the market: The Iranian government has been making efforts to increase the production of generic drugs in the country. This has led to an increase in the availability of generic antiviral drugs in the market. The market is also witnessing an increase in the number of local pharmaceutical companies that are manufacturing antiviral drugs. This has led to increased competition, which has resulted in lower prices for customers.
Local special circumstances: The Iranian government has implemented price control policies on pharmaceutical products, including antiviral drugs. This has resulted in lower prices for customers, but it has also led to a decrease in the profit margins for pharmaceutical companies. The government has also implemented policies to encourage the local production of pharmaceutical products, which has led to an increase in the number of local companies manufacturing antiviral drugs.
Underlying macroeconomic factors: The Iranian economy has been facing challenges due to the sanctions imposed by the United States. This has led to a decrease in the value of the Iranian currency, which has made it difficult for the country to import pharmaceutical products. As a result, the government has been encouraging the local production of pharmaceutical products to reduce the country's reliance on imports. The high prevalence of viral diseases in the country has also contributed to the demand for antiviral drugs. In conclusion, the Antiviral Drugs market in Iran is developing due to the high prevalence of viral diseases in the country, the government's efforts to increase the local production of pharmaceutical products, and the customers' preference for generic drugs. The market is expected to continue to grow in the future due to the increasing demand for antiviral drugs in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
